MRK vs TSLA: Which Is the Better Buy?

Side-by-side comparison of Merck & Co., Inc. and Tesla, Inc. โ€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-26.
Merck & Co., Inc. ยท Healthcare
$147.17
-4.1% upside to fair value
Med Conviction Grade C
VS
Tesla, Inc. ยท Consumer Cyclical
$372.11
+45.0% upside to fair value
Med Conviction Grade C
QuantHub Verdict
TSLA has more upside to fair value (+45.0%). These are model outputs โ€” not personalized investment advice. See all research โ†’
Valuation & Fundamentals
Metric MRK TSLA
Current Price $147.17 $372.11
Fair Value Estimate $141.07 $539.56
Upside to Fair Value -4.1% +45.0%
Market Cap $363.5B $1,469.7B
Forward P/E โ€” โ€”
EV / EBITDA 29.6x 121.7x
Price / Sales 5.5x 14.2x
Price / FCF 22.6x 209.1x
Revenue Growth YoY +5.1% +25.5%
Gross Margin 75.4% 18.9%
Operating Margin 16.7% 4.2%
Return on Equity 6.6% 4.6%
Dividend Yield 2.31% 0%
FCF Yield 4.42% 0.48%
Analyst Consensus Buy Hold
Investment Thesis
MRK โ€” Merck & Co., Inc.
Merck & Co., Inc. is a global healthcare leader with two core divisions, Pharmaceuticals and Animal Health, spanning oncology, vaccines, acute hospital care, immunology, neuroscience, virology, cardiovascular and diabetes, and it employs roughly 74,000 people under CEO Robert Davis. The business quality is medium: TTM gross margin of 75.4% and TTM operating margin of 16.7% reflect a genuinely higโ€ฆ
TSLA โ€” Tesla, Inc.
Tesla, Inc. designs, manufactures and sells electric vehicles and energy generation and storage systems, operating through Automotive and Energy Generation and Storage segments with 134,785 full-time employees and a market capitalization of $1,469.67 billion at a share price of $372.11. The business quality is mixed: revenue grew 25.5% year over year in the most recent quarter, but earnings fell โ€ฆ
Accumulation Zones
Metric MRK TSLA
Zone Low $105.80 $404.67
Zone High $119.91 $458.63
In Buy Zone? No Yes
โ† MRK Research    TSLA Research โ†’    All Research